Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model
Abstract
Oncolytic herpes simplex viruses are proving to be effective in clinical trials against a number of cancers. Here, R-115, an oncolytic herpes simplex virus retargeted to human erbB-2, fully virulent in its target cells, and armed with murine interleukin-12 was evaluated in a murine model of glioblastoma. We show that a single R-115 injection in established tumors resulted, in about 30% of animals, in the complete eradication of the tumor,...
Paper Details
Title
Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model
Published Date
Feb 12, 2019
Journal
Volume
38
Issue
23
Pages
4467 - 4479
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History